Reduced amplitude of the sural nerve sensory action potential in PARK2 patients

Y Ohsawa; K Kurokawa; M Sonoo; H Yamada; S Hemmi; K Iwatsuki; H Hagiwara; T Murakami; T Shirabe; T Shimizu; Y Sunada

doi:10.1212/01.wnl.0000171859.85078.3d

Reduced amplitude of the sural nerve sensory action potential in PARK2 patients

Neurology. 2005 Aug 9;65(3):459-62. doi: 10.1212/01.wnl.0000171859.85078.3d.

Authors

Y Ohsawa¹, K Kurokawa, M Sonoo, H Yamada, S Hemmi, K Iwatsuki, H Hagiwara, T Murakami, T Shirabe, T Shimizu, Y Sunada

Affiliation

¹ Division of Neurology, Department of Internal Medicine, Kawasaki Medical School, Kurashiki-City, Okayama 701-0192, Japan.

PMID: 16087916
DOI: 10.1212/01.wnl.0000171859.85078.3d

Abstract

The authors performed nerve conduction studies in nine PARK2 and eight idiopathic Parkinson disease patients and found a significant reduction of sural sensory nerve action potential (SNAP) amplitude in eight PARK2 patients who mostly remained asymptomatic. These data suggest that sensory axonal neuropathy may be a common clinical feature of PARK2 and a reduced amplitude of sural SNAP could be a diagnostic indicator of PARK2.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Action Potentials / physiology
Adult
Electrodiagnosis
Female
Ganglia, Spinal / metabolism
Ganglia, Sympathetic / metabolism
Humans
Male
Middle Aged
Neural Conduction / physiology
Paresthesia / diagnosis
Paresthesia / etiology
Paresthesia / physiopathology
Parkinsonian Disorders / complications*
Parkinsonian Disorders / diagnosis*
Parkinsonian Disorders / physiopathology
Peripheral Nervous System Diseases / diagnosis*
Peripheral Nervous System Diseases / etiology*
Peripheral Nervous System Diseases / physiopathology
RNA, Messenger / metabolism
Sensation Disorders / diagnosis*
Sensation Disorders / etiology*
Sensation Disorders / physiopathology
Sural Nerve / physiopathology*
Ubiquitin-Protein Ligases / genetics

Substances

RNA, Messenger
Ubiquitin-Protein Ligases
parkin protein